Baxter International (NYSE:BAX) is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.
In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters. The company’s medication delivery products include infusion pumps, administration sets and patient-controlled analgesia systems, while its parenteral nutrition and pharmacy automation solutions help healthcare providers manage and deliver intravenous nutrition and medication safely and efficiently.
Baxter’s surgical and bioScience portfolio features advanced surgical sealants, hemostats and adhesion barriers, as well as devices for cell therapy, membrane plasmapheresis and laboratory separations. These products support a range of critical care applications, from intraoperative bleeding control to therapeutic apheresis and regenerative medicine research.
Founded in 1931 and headquartered in Deerfield, Illinois, Baxter operates in more than 100 countries and employs over 50,000 people. The company is led by Chairman and Chief Executive Officer José E. Almeida, under whose leadership Baxter has continued to invest in research and development, strategic partnerships and targeted acquisitions aimed at addressing evolving patient and healthcare provider needs around the world.
